At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 19 enrolled
Drug / intervention
TALIMOGENE LAHERPAREPVEC (TVEC) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
In Brief
A Phase 2 clinical trial evaluating TALIMOGENE LAHERPAREPVEC (TVEC) and Hypofractionated Radiotherapy for Melanoma and 2 related conditions. Completed, enrolled 19 participants across 3 sites.
Detailed Summary
The purpose of this phase II clinical study is to test the good and bad effects of T-VEC (talimogene laherparepvec) with or without hypofractionated radiotherapy on people with melanoma, Merkel cell carcinoma, or other solid tumors with skin metastasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma, Merkel Cell Carcinoma, Other Solid Tumors
CountriesUnited States
CollaboratorsAmgen
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJun 2016
First PostedJun 2016
Primary CompletionFeb 2024
TodayJul 2026
First PostedJun 30, 2016
Enrollment StartJun 21, 2016
Primary CompletionFeb 22, 2024
TodayJul 2, 2026
Enrollment to primary: 7.7 yearsPosted 10.0 years ago
Interventions
TALIMOGENE LAHERPAREPVEC (TVEC)drug
Hypofractionated Radiotherapyradiation